Upgrade Your Browser
We no longer support this version of your browser.
We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.
Return to the course you were viewing
People are asking when rimonabant will be approved.
Not for a few years...and possibly never.
Rimonabant (Acomplia, Zimulti) has been in the news as a promising drug for obesity, smoking cessation, dyslipidemia, and diabetes.
Pharmacist's Letter Canada includes:
Already a subscriber? Log in
Volume pricing available. Get quote